Pharmaceuticals

Innovating tomorrow

A little girl playing with a teddy bear in a living room.

Demographic change has repercussions for the health care system. The number of patients with chronic conditions and multiple morbidities is on the rise. At the same time, people are taking a more active role in managing their own health. With our innovative products, we seek to achieve therapeutic benefits for patients, while at the same time satisfying the growing requirements of physicians and health insurers. In addition to the local business based in Zurich, the global headquarters for the therapeutic areas of oncology, ophthalmology and hematology has been located in Basel since 2012/2013.

Bayer operates in the following therapeutic areas in Switzerland:

Eye diseases
Women's health
Hematology
Cardiovascular diseases
Infectious diseases
Cancer
Pulmonary hypertension
Men's Health
Neurology
Radiology

Clinical Trials

In 2020, Bayer (Schweiz) AG began publishing the results of clinical studies on drugs that are approved on the Swiss market and contain new active ingredients. We have compiled the links to these results in the following document, which we will update as and when necessary.

Nubeqa clinical study results (PDF 85.72 KB)

Verquvo clinical study results (PDF 133.59 KB)

Kerendia clinical study results (PDF 72.52 KB)

(Overview from April 12, 2023)

You can find further information about the clinical studies conducted by Bayer here.

PP-OTH-CH-0074-1 2406